Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Earnings callNasdaq· January 16, 2026

Aehr Test (AEHR) Q2 2026 Earnings Call Transcript

View original at nasdaq.com
Aehr Test (AEHR) Q2 2026 Earnings Call Transcript Image source: The Motley Fool. DATE Thursday, January 8, 2026 at 5:00 p.m…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Single AI processor wafer-level testing requires 20-30 systems at $4M-$5M each

    80% confidence
  • Testing and burning-in full wafers of GaN power semiconductors with up to 600 volts or more is not easy

    80% confidence
  • Lead Sonoma production customer provided very large forecast with shipments expected to start Q1 FY2027

    80% confidence
  • AI test and burn-in spending is currently $8B to $15B

    80% confidence
  • Aehr is not profitable at current revenue levels

    80% confidence
  • Aehr is the leading provider for HTOL testing of AI processors in test houses worldwide

    80% confidence
  • High Bandwidth Flash (HBF) development would take 1+ year after customer commitment

    80% confidence
  • Bookings forecast of $60M to $80M for second half FY2026 based on customer forecasts recently provided to Aehr

    80% confidence
  • The AI business opportunity for Aehr Test can be measured in hundreds of millions of dollars within a few years

    80% confidence
  • Aehr production capacity exceeds 20 systems per month at either package or wafer level, and can ship 20 per month of each if needed

    80% confidence
  • At least one customer is transitioning HTOL to production in late calendar 2026

    80% confidence
  • WaferPak design turnaround time is 8 weeks with Design for Test (DFT) lower pin count modes

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com